Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
about
Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectivesVascular endothelial growth factor as an anti-angiogenic target for cancer therapySimultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.Single variable domain-IgG fusion. A novel recombinant approach to Fc domain-containing bispecific antibodies.Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.The VEGF family in cancer and antibody-based strategies for their inhibition.Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Antibody phage display libraries: contributions to oncology.Ramucirumab: preclinical research and clinical development.Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26.Ramucirumab: successfully targeting angiogenesis in gastric cancer.Clinical advances in the development of novel VEGFR2 inhibitors.Biomarkers for anti-angiogenic therapy in cancer.The origin of CDR H3 structural diversity.Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel futureChemomechanical mapping of ligand-receptor binding kinetics on cells.Generation of Potent Anti-Vascular Endothelial Growth Factor Neutralizing Antibodies from Mouse Phage Display Library for Cancer Therapy.Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.Update on Anti-Angiogenesis Therapy in Colorectal Cancer.Ramucirumab for the treatment of gastroesophageal cancers.The functionalized human serine protease granzyme B/VEGF₁₂₁ targets tumor vasculature and ablates tumor growth.State of the art in anti-cancer mAbs.Ramucirumab (IMC-1121B): a novel attack on angiogenesis.Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.Targeting the vasculature of visceral tumors: novel insights and treatment perspectives.Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.Anti-angiogenic agent ramucirumab: meaningful or marginal?Molecular and chemical engineering of bacteriophages for potential medical applications.An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors.Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.Current status of ramucirumab in gastroesophageal adenocarcinoma.Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Phage display-derived human antibodies in clinical development and therapy
P2860
Q26826817-14575A6B-25A8-4EDE-94D5-3BD13F6E5C16Q30455612-D50F2C5E-87EB-4564-A5D2-0C7445F7D468Q31016741-31798B84-C74E-4894-B805-D680363E5943Q33216322-0B5F6BA0-8E32-4167-AC73-236FAFA7A848Q33234057-C4B28991-EA4B-4CA8-813C-9B5EA50910CDQ33418595-75FD526C-758F-4937-A1A2-1071A2DCEB15Q33457195-3554305F-FA8D-4D5B-B72E-B21D34CBF988Q33710574-76EE7E86-97CD-4A54-A99F-11DB83AC9E4CQ33733437-70E6B501-F7F4-4002-8BB4-812C3F50C684Q34273411-1C924C13-6D29-45D0-A6D6-E3217C3F7DC0Q34323991-1521FA20-9AA1-47F0-BF1A-921EBB97A1ACQ34446310-74AA0872-BCBB-42F2-B134-B442AE582EDFQ34521999-470363C5-F724-40CD-9832-182E389085BAQ34616558-8A77A081-345A-448F-B695-A4A1647F7BF2Q34658366-D9D97197-0AC5-4FEE-A677-B69D585E3F8CQ34695003-5FCAAE31-CEAA-4C8E-B947-0BCA13DE1D77Q35054394-950E84DA-F524-4D48-BA40-27D415D933E7Q35525772-78030806-B1D7-4741-A32F-BF5C161B44D9Q35622461-4BF6DCB5-BCA3-487A-A5B4-72F34F5282D1Q35640101-04793960-DDB6-4002-A578-0E1CD3C126CFQ35834533-C6A70C6D-2ED5-41B9-B2DC-F7D61511F7CEQ35918945-D730FF4E-14E4-42F0-AA32-F09AA788CE93Q36392642-FD940A43-530A-423D-9624-DB0641341601Q37190578-4CC17562-A21C-4223-A7DE-34D0AE56688CQ37211153-9395FF23-238F-43FF-8E02-C41D0B0020FAQ37577621-C133997E-6A78-40E2-A740-D07B88B06735Q37655585-9B3B2123-519D-4E77-BB0F-404BCA1F60FFQ37771954-BC3D8FA5-7315-441F-8B7B-38B222DA659FQ37827451-C809DAE9-F932-42DE-B2D5-C419446ED08FQ37993393-B7760D27-1B31-454E-A84D-2CAC240367EEQ38166329-A6BEC72A-1023-4E1E-9928-780ACA8F6776Q38194159-D81C77FB-B67E-4F1F-A022-A20253457628Q38232491-0775B536-63BC-45BC-9BE1-D982ECDB6026Q38410220-554C591A-4B19-48E4-A889-721323B61B1CQ38513056-8EA73470-1B55-4D38-88F8-071314FABE94Q38550459-E1981067-48AC-49CB-A880-64E48116901BQ38691733-9BE46409-8AFA-4BD6-A733-B50CC9DE3A8EQ38820756-FBB5B199-C548-4382-89DB-0502B4329464Q39401628-360B00EA-8613-4385-8A5A-15BB4D79792AQ41416393-004EA068-7F71-44A3-8107-60A44E31A041
P2860
Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Selection of high affinity hum ...... for antiangiogenesis therapy.
@ast
Selection of high affinity hum ...... for antiangiogenesis therapy.
@en
type
label
Selection of high affinity hum ...... for antiangiogenesis therapy.
@ast
Selection of high affinity hum ...... for antiangiogenesis therapy.
@en
prefLabel
Selection of high affinity hum ...... for antiangiogenesis therapy.
@ast
Selection of high affinity hum ...... for antiangiogenesis therapy.
@en
P2093
P2860
P356
P1476
Selection of high affinity hum ...... for antiangiogenesis therapy.
@en
P2093
Haifan Zhang
Larry Witte
Peter Bohlen
Xenia Jimenez
Zhenping Zhu
P2860
P304
P356
10.1002/IJC.1634
P577
2002-01-01T00:00:00Z